Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Low platelet count

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    485 result(s) found for: Low platelet count. Displaying page 1 of 25.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-000965-34 Sponsor Protocol Number: E5501-G000-310 Start Date*: 2014-05-27
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia ...
    Medical condition: Thrombocytopenia in Patients with Chronic Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    18.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    18.0 10005329 - Blood and lymphatic system disorders 10039884 Secondary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) GB (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004032-21 Sponsor Protocol Number: ARGX-113-2004 Start Date*: 2021-05-07
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immu...
    Medical condition: Primary immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10083843 Primary immune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) PT (Completed) DE (Completed) BG (Completed) NO (Completed) DK (Completed) GR (Completed) IT (Completed) FR (Completed) RO (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000934-36 Sponsor Protocol Number: E5501-G000-311 Start Date*: 2014-06-16
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia ...
    Medical condition: Thrombocytopenia in Patients with Chronic Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    18.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    18.0 10005329 - Blood and lymphatic system disorders 10039884 Secondary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-000017-20 Sponsor Protocol Number: ASS-Metamizol-DDI Start Date*: 2018-07-17
    Sponsor Name:Universitäts-Herzzentrum Freiburg • Bad Krozingen
    Full Title: Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole)
    Medical condition: Antithrombotic therapy after surgical replacement of stenotic heart valve by a bioprosthesis or mitral valve repair
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000830-12 Sponsor Protocol Number: E5501-G000-302 Start Date*: 2012-08-28
    Sponsor Name:Eisai Limited
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care...
    Medical condition: Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    16.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    16.1 10005329 - Blood and lymphatic system disorders 10036735 Primary thrombocytopenia LLT
    16.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002471-34 Sponsor Protocol Number: AZA-MDS-003 Start Date*: 2012-11-23
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red...
    Medical condition: Subjects with Red Blood Cell Transfusion-Dependent Anemia and Thrombocytopenia due to IPSS Lower-Risk Myelodysplastic Syndromes
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) SE (Completed) ES (Ongoing) CZ (Completed) PT (Completed) LT (Completed) IT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) DK (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000831-10 Sponsor Protocol Number: E5501-G000-305 Start Date*: 2012-07-16
    Sponsor Name:Eisai Limited
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, i...
    Medical condition: Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    14.1 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    14.1 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    14.1 10005329 - Blood and lymphatic system disorders 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004295-22 Sponsor Protocol Number: NL59645.098.16 Start Date*: 2017-04-10
    Sponsor Name:Hagaziekenhuis
    Full Title: Treatment of thromBocytopenia with EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients with Immune ThrombocytoPenia.
    Medical condition: Immune thrombocytopenia patients with low platelets and in need of surgery.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10023095 ITP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003232-24 Sponsor Protocol Number: AVA-PED-301 Start Date*: 2020-12-03
    Sponsor Name:Dova Pharmaceuticals, Inc.
    Full Title: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment...
    Medical condition: Thrombocytopenia in paediatric subjects with immune thrombocytopenia for ≥6 months duration who have had an insufficient response to a previous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043555 Thrombocytopenias HLT
    23.0 10005329 - Blood and lymphatic system disorders 10083843 Primary immune thrombocytopenia LLT
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    20.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004886-42 Sponsor Protocol Number: TRA114389 Start Date*: 2013-04-01
    Sponsor Name:University of Crete
    Full Title: Study of the effect of the thrombopoietin receptor agonist eltrombopag on thrombocytopenia and megakaryopoiesis of patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Medical condition: Patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004012-19 Sponsor Protocol Number: PRN1008-010(DFI17124) Start Date*: 2018-03-12
    Sponsor Name:Principia Biopharma, a Sanofi Company
    Full Title: An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib (PRN1008), an Oral BTK Inhibitor, in Patients with Relapsed...
    Medical condition: Immune Thrombocytopenia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) BG (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007258-75 Sponsor Protocol Number: 20060198 Start Date*: 2008-08-22
    Sponsor Name:Amgen Inc
    Full Title: A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndr...
    Medical condition: Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). ------------------------------------------------------------------------------ Síndrome Mielodisplásico (SMD) de Riesgo Bajo o Intermedio-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Prematurely Ended) NL (Completed) CZ (Prematurely Ended) IE (Completed) AT (Prematurely Ended) DE (Completed) HU (Completed) BE (Completed) GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004103-12 Sponsor Protocol Number: TAK-079-1004 Start Date*: 2021-02-22
    Sponsor Name:Takeda Development Center Americas, Inc. (Takeda)
    Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed) BG (Completed) HR (Completed) IT (Completed) ES (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003038-26 Sponsor Protocol Number: ARGX-113-1603 Start Date*: 2017-02-08
    Sponsor Name:Argenx BVBA
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Op...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10074678 Primary immune thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000884-26 Sponsor Protocol Number: TP0003 Start Date*: 2020-03-20
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chroni...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) HU (Completed) BE (Completed) CZ (Completed) AT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) GR (Completed) IT (Prematurely Ended) HR (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000114-19 Sponsor Protocol Number: TRC114968 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). A...
    Medical condition: Thrombocytopenic Subjects with advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10060356 Acute myeloid leukaemia without mention of remission LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GR (Completed) ES (Completed) IE (Completed) PL (Completed) HU (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002063-60 Sponsor Protocol Number: PRN1008-018(EFC17093) Start Date*: 2020-11-12
    Sponsor Name:Principia Biopharma, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults...
    Medical condition: Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10074667 Immune thrombocytopenic purpura LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) AT (Completed) NO (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002100-41 Sponsor Protocol Number: ARGX-113-1801 Start Date*: 2019-11-01
    Sponsor Name:argenx BVBA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immun...
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) HU (Completed) CZ (Completed) ES (Completed) PL (Completed) BE (Completed) DE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003451-11 Sponsor Protocol Number: TP0006 Start Date*: 2020-04-30
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chroni...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) DK (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004683-22 Sponsor Protocol Number: RGCH005 Start Date*: 2020-10-16
    Sponsor Name:Ostfold Hospital Trust
    Full Title: Daratumumab as a treatment for adult immune thrombocytopenia
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) FR (Completed) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:00:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA